No content results match your keyword.
Content
You have successfully logged out.
Not registered yet?
Lipofundin® and Lipidem® emulsion for infusion
Lipofundin® and Lipidem® provide the macronutrient component in parenteral nutrition regimens. These lipids or fats are a source of energy and are important for absorbing fat-soluble vitamins.
As the innovator of the proven medium chain triglyceride / long chain triglyceride technology, improving patient outcomes is always our focus. Our products can be tailored and adapted to individual patient needs
By clicking 'Confirm” you declare that you are a health care professional. If you are a member of the public, we will redirect you to the pages dedicated to you.
Confirm Yes, I am a health care professional. Cancel No, I am not a health care professional.B. Braun’s second-generation lipid
Lipofundin®
In 1998, B. Braun launched our second-generation lipid: Lipofundin® MCT/LCT. The solution is a physical emulsion mix derived from 50% MCT from Coconut Oil and 50% LCT (EFAs*) from Soya Bean Oil.
Our lipid emulsion ensures the supply of essential fatty acids as part of complete parenteral nutrition when oral or enteral nutrition is impossible, insufficient, or contraindicated.
Indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition.
*EFA - Essential Fatty Acid
Clinical benefits when comparing MCT/LCT to 100% LCT:
B. Braun’s third-generation lipid
Lipidem®
In 2005, B. Braun launched Lipidem®, our third-generation MCT/LCT lipid emulsion containing Omega-3-Acid triglycerides from fish oil. Omega-3-acid-triglycerides from fish oil, containing high levels of EPA* and DHA**, may have positive effects on diseases such as hypertension, arthritis, atherosclerosis, depression, adult-onset diabetes mellitus, myocardial infarction, thrombosis and some cancers10. Both EPA and DHA are fundamentally important fatty acids and known factors which influence the pattern of inflammation regulating eicosanoids and cytokines11.
Licensed from pre-term neonates to adults, Lipidem® is suitable for peripheral venous administration and can also be administered separately via peripheral veins as part of total parenteral nutrition
Indicated for supply of energy, including a readily utilisable lipid component (MCT) and essential omega-6 fatty acids and omega-4 fatty acids, as part of parenteral nutrition when oral or enteral nutrition is impossible, insufficient or contraindicated
*EPA – Eicosapentaenoic Acid
**DHA – Docosahexaenoic Acid
0%
Coconut Oil
Medium-chain triglycerides
Source of readily available energy
0%
Soya Bean Oil
Long-chain triglycerides
Source of EFA’s (essential fatty acids) and energy
0%
Omega-3-Acid Triglycerides
From fish oil for the delivery of EPA and DHA
There are multiple benefits of using MCT/LCT with Omega-3-Acid triglycerides from fish oil. The combination of MCT/LCT with Omega-3-Acid triglycerides from fish oil has shown an improvement in gas exchange in septic patients in the ICU, when compared with MCT/LCT on its own12. ICU patients experienced a reduced risk of nosocomial infections when there was involvement of Omega-3 with MCT/LCT13 when compared with a fish oil free lipid.
Using Omega-3 with MCT/LCT led to the duration of hospital stays in patients requiring prolonged parenteral nutrition undergoing abdominal surgery, decrease when compared to 100% LCT14.
XX-WEBLE-05-24
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to B. Braun Medical Ltd (0800 298 0299).
XX-WEBNT-05-24
References
